The Company: Horizontal SaaS for revenue operations. $2.2M ARR at time of close, 115% NRR, growing 70% year over year.
The Outcome: Closed an $8M Series A after five months of fundraising. Eighteen months later, the company laid off 40% of staff, failed to raise Series B, and sold for parts in an acqui-hire that returned nothing to common shareholders.
The raise was the success story. The outcome was the failure.
The terms the founder accepted under pressure created a set of constraints that made the company nearly impossible to finance again. The raise did not save the company. It set the trap.
What Happened
Months 1 through 3: The Grind
The founder, call him David, started raising in January. Strong metrics. Good team. Reasonable pitch. But the market was cooling and revenue operations was getting crowded. Fifteen meetings in the first month produced zero term sheets.
By month two, David had burned through his top-choice investors. He moved to his B-list, then his C-list. The backchannel was forming: “Good founder, crowded space.” He started hearing the same objections in different voices. Market size. Competitive intensity. Differentiation.
By month three, David was running low on new names. His runway was at seven months. His board was nervous. His VP of Engineering asked him point-blank: “Are we going to make it?”
Month 4: The Lifeline
A growth-stage fund that David had not originally targeted came in with interest. They moved fast. Two meetings in one week. A partner visit to the office. They seemed genuinely excited.
David felt the relief before the term sheet arrived. After three months of rejection, someone finally saw what he saw. He told his board. He told his team. The energy shifted overnight.
Month 5: The Term Sheet
The term sheet arrived on a Friday afternoon. David had 72 hours to respond.
Here is what it contained:
| Term | Details |
|---|---|
| Investment | $8M |
| Pre-money valuation | $40M |
| Liquidation preference | 1.5x participating preferred |
| Board seats | 2 investor, 1 founder, 1 independent (investor-approved) |
| Anti-dilution | Full ratchet |
| Pro-rata rights | Super pro-rata on next round |
| Protective provisions | Consent required for any financing, acquisition, or key hires |
David’s lawyer flagged concerns. His seed investors flagged concerns. His advisor flagged concerns.
David signed on Monday.
The Three Terms That Destroyed Him
1. The $40M Valuation
David’s company had $2.2M ARR growing 70% year over year. A $40M pre-money valuation implied an 18x revenue multiple.
In a hot market, this would have been aggressive but defensible. In the market David was raising in, it was a trap. Here is why.
To raise a Series B at an acceptable step-up, David would need to justify a $120M to $160M valuation within 18 to 24 months. That required roughly $8M to $10M ARR at a 15x to 20x multiple, or $6M to $7M ARR at a higher multiple driven by exceptional growth and retention.
From $2.2M ARR, reaching $8M ARR in 18 months required tripling and then some. Not impossible. But it required everything to go right: sales hires ramping on schedule, churn staying low, expansion revenue accelerating, and zero market headwinds.
David did not have margin for a single bad quarter. The valuation removed all room for error.
2. The 1.5x Participating Preferred
Most Series A term sheets include a 1x non-participating liquidation preference. This means investors get their money back or their pro-rata share of proceeds, whichever is greater.
David’s term sheet included a 1.5x participating preference. This meant his investors would get 1.5 times their investment ($12M) before anyone else received a dollar, and then also participate in the remaining proceeds based on their ownership percentage.
In an upside scenario (large exit), this barely matters. In a moderate scenario (the most likely outcome for most startups), it is devastating. If David’s company sold for $50M, his investors would take $12M off the top plus their percentage of the remaining $38M. Common shareholders, including David and his team, would split what was left.
The participating preference turned every exit below $200M into a bad outcome for the founder and employees.
3. The Full Ratchet Anti-Dilution
Standard anti-dilution protection is weighted average: if a down round happens, existing investors get some additional shares to compensate, but the adjustment is proportional.
Full ratchet is different. If David raised any future round at a lower price per share, his Series A investors would be repriced as if they had invested at the lower price. Every share.
This meant that a down round would not just dilute David. It would massively dilute him, because the Series A investors’ ownership would expand to reflect the new, lower price while everyone else absorbed the dilution.
The full ratchet made a flat or down Series B almost impossible to execute. Any new investor modeling the deal would see that a significant portion of their capital would go toward compensating the Series A investors rather than funding the company.
The three terms interacted with each other. The high valuation made a down round likely. The full ratchet made a down round catastrophic. The participating preference made moderate exits worthless. Together, they created a cage that only a massive outcome could escape.
The Eighteen Months That Followed
Months 1 through 6: The Hiring Sprint
David’s board pushed for aggressive growth to justify the valuation. He hired twelve people in six months. Two senior sales reps, a VP of Marketing, three engineers, a head of customer success, and support staff. Burn rate went from $180K per month to $420K per month.
Revenue grew, but not fast enough. By month six, ARR was at $3.1M. Strong growth in absolute terms. Not on pace for the $8M required to justify a clean Series B.
Months 7 through 12: The Slowdown
One of the senior sales reps did not work out. Pipeline that looked strong in Q1 slipped into Q3. A key customer churned. NRR dropped from 115% to 104%.
None of these were catastrophic in isolation. Every startup faces quarters like this. But David did not have room for a normal quarter. He needed exceptional quarters, every quarter, for 18 months straight. One normal quarter broke the trajectory.
By month twelve, ARR was at $4.1M. Still growing. Still a real company. But the Series B math no longer worked. To raise at a step-up from $40M, he needed to show acceleration. Instead, he was showing deceleration.
Months 13 through 18: The Spiral
David’s board, now controlled by his Series A investors, pushed for a pivot to enterprise. Larger deals, higher ACV, faster path to the revenue number. David disagreed. His product was built for mid-market. Enterprise would require six months of development and a different sales motion.
The board overruled him. David spent three months pursuing enterprise deals that did not close. The mid-market pipeline, now neglected, dried up. By month fifteen, new bookings had dropped 40% from their peak.
At month sixteen, David tried to raise a bridge. His Series A investors passed. The full ratchet provision made it nearly impossible for anyone else to invest at a reasonable valuation. Any bridge at a lower price would trigger the ratchet and wipe out the common shareholders.
At month eighteen, the company accepted an acqui-hire offer from a larger enterprise software company. The purchase price was $14M. After the 1.5x participating preference ($12M to the Series A investors) and legal fees, common shareholders received approximately $300K to split among the founding team and 30 employees.
David’s four years of work returned less than a year of his forgone salary.
Where It Went Wrong
The obvious answer is: the terms. And that is partially right. But the deeper answer is that the terms were a consequence of a process failure that began months earlier.
Failure 1: He raised from desperation, not strength.
By month five of his fundraise, David was not choosing an investor. He was accepting a rescue. The power dynamic was inverted, and the terms reflected it. Every aggressive provision in the term sheet was a direct result of the investor knowing they were the only option.
Failure 2: He did not walk away.
David’s lawyer told him the terms were unusual. His seed investors told him to negotiate. His advisor told him to push back on the ratchet at minimum. David was too afraid. He believed that pushing back would kill the deal, and that no deal meant the company died.
He was probably wrong. Most term sheet negotiations do not kill deals. Investors expect pushback. The provisions that seem non-negotiable are often the first to move. David never tested this because he was negotiating from fear.
Failure 3: He let the valuation flatter him.
Forty million dollars pre-money. After three months of being told his company was not good enough, someone was telling him it was worth $40M. The validation was intoxicating. David did not interrogate why the valuation was so high.
The answer was simple. The investor offered a high valuation because the other terms more than compensated for it. A $40M valuation with 1.5x participating preferred, full ratchet, and board control is not a $40M bet on the founder. It is a structured deal that protects the investor in every scenario except the one where the founder wins big.
Failure 4: He did not model the outcomes.
David never built a simple scenario analysis of what the terms meant across different exit values. If he had, he would have seen that for any exit below $150M, his outcome was nearly identical to failure. The terms created a binary: massive success or nothing.
A term sheet is not a gift. It is a contract that defines your future for the next five to ten years. Read it as the other side's best-case scenario for themselves, not as validation of your company's worth.
What He Should Have Done
Option A: Walk away from the term sheet. Raise a smaller bridge from existing investors. Cut burn. Come back to the market in six months with cleaner metrics and more leverage. This is terrifying and often correct.
Option B: Negotiate the terms aggressively. Accept the valuation haircut in exchange for clean terms. A $25M pre-money with 1x non-participating, weighted average anti-dilution, and founder-controlled board would have been a fundamentally different deal. Less flattering. Far more survivable.
Option C: Negotiate the specific terms that killed him. At minimum: convert the participating preferred to non-participating, the full ratchet to weighted average, and take back one board seat. These three changes alone would have turned a trap into a workable deal.
David did none of these because he was afraid the deal would disappear. That fear cost him his company.
The Meta-Lesson
Closing a round is not winning. Closing a round on terms that give you a viable path to the next milestone is winning. Everything else is a slower, more painful version of failure.
The most dangerous moment in a fundraise is not the rejection. It is the term sheet that arrives when you are desperate. That is when founders make the decisions they spend years regretting.
If the only term sheet on the table requires everything to go perfectly for you to survive, it is not a lifeline. It is a trap with a longer fuse.
The courage to walk away from a bad term sheet is the most valuable and rarest skill in fundraising. It is also the one that no one teaches you until it is too late.